[The Clinical Characteristics and Prognosis of Patients with Light-Chain Amyloidosis: A Retrospective Analysis].
In recent years, the survival rate of patients with AL amyloidosis has improved significantly, but the 5-year survival rate is still relatively low. Cardiac biomarkers (NT-proBNP and hs-cTnI) and Mayo 2012 stage at diagnosis continue to provide important prognostic information. Bortezomib-based regimens were used as the primary treatment in most patients, and the addition of daratumumab is becoming increasingly common.
Authors
- Dan Zhao (ORCID: https://orcid.org/0000-0001-7066-9058)
- Bing Yao (ORCID: https://orcid.org/0000-0002-6657-2760)
- Tingting Chen (ORCID: https://orcid.org/0000-0002-2227-3208)
- Zeng-Kai Wang
Institutions
- Dalian Medical University (CN)
- Dalian Municipal Central Hospital (CN)
- First Affiliated Hospital of Dalian Medical University (CN)
Publication Details
- Journal
- PubMed
- Published
- 2025-04-01
- DOI
- https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.043
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article